<DOC>
	<DOCNO>NCT02672163</DOCNO>
	<brief_summary>This study aim evaluate safety clinical feasibility epicardially deliver autologous atrial appendage micrografts treatment heart failure . The micrografts consist atrial-derived cell extracellular matrix , place infarction scar CABG surgery .</brief_summary>
	<brief_title>Autologous Atrial Appendage Derived Cells Treatment Heart Failure</brief_title>
	<detailed_description>The atrial appendage tissue reservoir cardiomyocyte stem precursor cell . During coronary artery bypass graft ( CABG ) surgery part right atrial appendage excise upon insertion right atrial cannula heart-lung machine . This study aim address surgical feasibility patient safety epicardially deliver atrial appendage micrografts CABG surgery . Autologous cardiac cell harvest right atrial appendage CABG six patient . Micrografts consist atrial appendage-derived cell ( AADCs ) extracellular matrix ( ECM ) atrial appendage mechanically process . The cell place tissue-engineered sheet fibrin gel tissue clue deliver epicardially top infarction scar . Parameters include echocardiography reflect cardiac insufficiency study pre- post-operatively well three six month follow-up . Cardiac functional magnetic resonance imaging perform preoperatively six-months follow-up . 20 patient recruited serve control group . They schedule elective CABG treat accord normal hospital protocol , without ECM sheet .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Informed consent obtain Left ventricular ejection fraction ( LVEF ) ≤50 % ≥15 % New York Heart Association ( NYHA ) Class IIIV heart failure symptom Heart failure due leave ventricular outflow tract obstruction History lifethreatening possibly repeat ventricular arrhythmias resuscitation , implantable cardioverterdefibrillator Stroke disable condition within 3 month screen Severe valve disease schedule valve surgery Renal dysfunction ( GFR &lt; 84 ml/min/1.73m ) Other disease limit life expectancy Contraindications coronary angiogram MRI Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>autologous micrografts</keyword>
	<keyword>heart failure</keyword>
	<keyword>coronary artery bypass surgery</keyword>
	<keyword>cell therapy</keyword>
	<keyword>atrial appendage</keyword>
	<keyword>epicardial cell delivery</keyword>
</DOC>